134 related articles for article (PubMed ID: 27974685)
41. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
42. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
43. Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma.
Shao D; Gao Q; Liang CH; Wang SX
Leuk Lymphoma; 2017 Jul; 58(7):1581-1588. PubMed ID: 27832711
[TBL] [Abstract][Full Text] [Related]
44. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
45. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
46. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
47. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck.
Suh C; Kang YK; Roh JL; Kim MR; Kim JS; Huh J; Lee JH; Jang YJ; Lee BJ
J Nucl Med; 2008 Nov; 49(11):1783-9. PubMed ID: 18927319
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
[TBL] [Abstract][Full Text] [Related]
51. [
Ding CY; Li H; Liu C; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1047-1052. PubMed ID: 28823266
[TBL] [Abstract][Full Text] [Related]
52. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
53. Predictive value of
Becker S; Vermeulin T; Cottereau AS; Boissel N; Vera P; Lepretre S
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2034-2041. PubMed ID: 28733763
[TBL] [Abstract][Full Text] [Related]
54. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
[TBL] [Abstract][Full Text] [Related]
55. Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer.
Oh JK; Chung YA; Kim YS; Jeon HM; Kim SH; Park YH; Chung SK
Biomed Mater Eng; 2014; 24(1):1173-84. PubMed ID: 24212011
[TBL] [Abstract][Full Text] [Related]
56. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis.
Zhou X; Lu K; Geng L; Li X; Jiang Y; Wang X
Medicine (Baltimore); 2014 Dec; 93(28):e258. PubMed ID: 25526450
[TBL] [Abstract][Full Text] [Related]
57. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
58. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
59. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
60. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
Karantanis D; Subramaniam RM; Peller PJ; Lowe VJ; Durski JM; Collins DA; Georgiou E; Ansell SM; Wiseman GA
Clin Lymphoma Myeloma; 2008 Apr; 8(2):94-9. PubMed ID: 18501102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
